<DOC>
	<DOCNO>NCT01983358</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics JPI-289 healthy male subject .</brief_summary>
	<brief_title>The Evaluation Safety , Tolerability Pharmacokinetics Stroke Targeting Drug Healthy Volunteers</brief_title>
	<detailed_description>tPA treatment use within 3 hour stroke onset treat efficacy , JPI-289 treatment ( PARP-1 inhibitor ) show treat efficacy 10 hour stroke onset . PARP-1 inhibitor add-on therapy tPA useful prevent social , economic loss physical , mental disable stroke . This clinical trial progress explore safety , tolerability , pharmacokinetic/pharmacodynamic property JPI-289 single dose escalation ( 7cohort ) . Investigational product medication level within 4 week evaluate safety tolerability patient Data Safety Monitoring Board ( DSMB ) compose 3 expert except principal investigator last visit . In level 6 patient investigational product 2 patient placebo allocate respectively double blind manner .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<criteria>19~55 year healthy male BMI measurement 20kg/m²~27kg/m² 90 ≤ SBP＜140 ( mmHg ) 60 ≤ DBP＜100 ( mmHg ) 45 ≤ Pulse rate＜100 ( bpm ) Signed inform consent participate voluntarily comply trial requirement For followup visit study period , blood sample availability History clinically significant hepatic , gastrointestinal , pulmonary , musculoskeletal , endocrine , psychiatric , hematooncologic , cardiovascular ( Specially asthma , obstructive pulmonary disease , peptic ulcer ) History skin disease graft affect absorption drug History drug abuse Positive urine drug screening Administrated investigational product previous clinical trial within 60 day screen test Donated blood within 60 day prior screen test</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>PARP-1 inhibitor</keyword>
</DOC>